Open AccessSMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
Author(s) -
Abdul Sattar,
Pia Thömmes,
Lloyd Payne,
Peter Warn,
Richard Vickers
Publication year - 2015
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkv005
Subject(s) - fidaxomicin , clostridium difficile , vancomycin , medicine , dosing , gastroenterology , microbiology and biotechnology , antibiotics , biology , bacteria , genetics , staphylococcus aureus
SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom